The Oncologic Drug Advisory Committee said the FDA should mandate a restricted distribution system for cancer patients given erythropoiesis-stimulating agents.
References and Resources
FDA.gov
Sponsored by The Doctor’s Channel
The Oncologic Drug Advisory Committee said the FDA should mandate a restricted distribution system for cancer patients given erythropoiesis-stimulating agents.
References and Resources
FDA.gov
Sponsored by The Doctor’s Channel
